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Cervical squamous cell carcinoma (SCC) and adenocarcinoma
may involve the ovary. Although it is not difﬁcult to diagnose in
most cases, on very rare occasions the presentation may show
symptoms related to an ovarian mass, with the cervical cancer
being undetected, especially endocervical adenocarcinoma [1,2].
This is important because the challenge of diagnosing primary
endocervical adenocarcinoma occurs especially in women who
show no symptoms, and have a grossly normal cervix and a
negative Pap smear [3]. The spread of cervical malignancy (both
SCC and adenocarcinoma) is often through lymphatic drainage or
direct invasion [4]; except some reports show that endocervical
adenocarcinoma carries a higher risk of ovarian metastases than
SCC of the cervix [5]. There is an apparent difference in the treat-
ment strategy for advanced cervical cancers and ovarian cancers
[6,7]. Therefore, making an accurate diagnosis before planning
therapy is of paramount importance. The following is a case report
of advanced cervical adenocarcinoma metastatic to the ovary
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1028-4559/Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. PublishedA 54-year-old menopausal woman (G3P3) visited the emer-
gency room due to acute sudden onset of abdominal pain after
several weeks of abdominal fullness. Her past medical history was
unremarkable. She did not have any Pap smears since the birth of
her last child (28 years previously). Physical examination revealed a
protuberant and tense abdomen, but the cervix was essentially
normal. Transvaginal ultrasound revealed a 15 cm complex cystic
mass lesion located at the right adnexal area accompanied with
massive ascites, but the uterus and the left ovary seemed to be
normal. Computed tomography identiﬁed and conﬁrmed the above
ﬁnding (Fig. 1). Serum tumor markers, including CA 125, CA 199,
and CEA were 286.0 U/mL, 209.0 U/mL, and 226.0 ng/mL, respec-
tively. Other investigations, including hematological and
biochemical tests, a chest X-ray, and upper and lower gastrointes-
tinal (GI) tract evaluations were within normal limits.
Under the diagnosis of ovarian malignancy, the patient under-
went a laparotomy. During surgery, a right ovarian cystic complex
mass with a mucinous component (Fig. 2) accompanied with
massive ascites (7000 mL) and peritoneal carcinomatosis was
found. The immediate frozen pathology report favored a diagnosis
of adenocarcinoma-mucinous type. Therefore, the patient under-
went an optimal debulking surgery, including total hysterectomy
(Fig. 3), bilateral salpingo-oophorectomy, infracolic omentectomy
and retroperitoneal lymph node sampling, and multiple biopsies.
However, the ﬁnal pathologic report was primary uterine endo-
cervical adenocarcinoma.
Pathologic features included hyperchromatic dysplasia of the
mucinous glandular cells of the uterine endocervix; the mucinous
tumor occupied the whole layer of the endocervix and extended to
the lower segment of the uterine body. Other sections of the right
ovary, appendix, omentum, abdominal wall, and mesentery all
showed tumor metastases with ﬂoating mucinous tumor cells
within an extensive mucin pool.
The patient was treated with adjuvant systemic chemotherapy
(8 cycles of topotecan [Hycamtin Injection, GlaxoSmithKline, Sanby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Computed tomography showing a 15 cm circumscribed, oval, and heteroge-
neously hypodense mass with a moderately enhancing solid component.
Fig. 3. Uterus specimen shows tumor invasion to the whole thickness of the uterine
cervix.
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Pharmachemie B.V. for TEVA Pharma B.V., Haarlem, The
Netherlands]), and was still alive at 15 months after the initial
operation. This case report is of educational value to clinicians, for
the following reasons.
Firstly, although secondary ovarian malignancies are not rare,
the diagnosis is still challenging. The most likely metastatic tumors
mimicking primary ovarian mucinous tumors are those of the GI,
pancreatic or biliary tract, and endocervical adenocarcinomas [8,9];
our current case report ﬁts into this grouping. The woman in the
current case had no apparent symptoms and also had a negative
cytological screening test (a negative Pap smear), all of which
contributed to the delayed diagnosis.
Secondly, it is widely accepted that a simple algorithm using
tumor size and laterality (bilateral tumors of any size, or unilateral
tumor <10 cm ¼ metastatic; unilateral tumor  10 cm ¼ primary)Fig. 2. A complex cystic right ovarian mass with a mucinous component.can accurately classify a substantial majority of tumors [8]. In
addition, the concept is that gynecological organ-related diseases
should always be kept in mind with women presenting with ascites
and adnexa masses, regardless of size status, accompanied with
massive ascites [10,11]; therefore, the tendency to diagnose pri-
mary ovarian cancer is alwaysmade, as with our current case, based
on its relatively high prevalence compared with other possibilities.
Yemelyanova and colleagues [12] reported that violations of these
rules occurred most frequently with pancreatic, small and large
bowel, and endocervical primary tumors, as these can give rise to
metastatic tumors that are large, unilateral, and often cysticmasses.
Furthermore, a gross cystic, solid, or mixed cystic and solid
appearance can be seen in borderline, primary mucinous carci-
noma, and metastatic ovarian tumors and does not help to distin-
guish between them [8].
Thirdly, the extent of disease may be helpful in differentiating
between primary and metastatic mucinous tumors [9]. Most pri-
mary mucinous ovarian carcinomas are usually early FIGO stage (I
and II) at presentation [13,14]. Further information includes a
smooth surface with no excrescences or surface implants [8].
Pathological features may be useful in making a distinction. Find-
ings favoring a secondary ovarian tumor include: (1) an inﬁltrative
invasion pattern; (2) small glands or tubules and single cells; (3)
lymphovascular space invasion; (4) a nodular growth pattern of
inﬁltrating tumor with intervening ovarian tissue containing
normal ovarian structures, often with stromal desmoplasia; (5)
hilar involvement; (6) microscopic surface invasion; and (7) the
presence of signet ring cells [8]. By contrast, features favoring a
primary ovarian tumor include: (1) an expansible invasion pattern
with a back-to-back neoplastic gland without intervening stroma;
(2) complex papillary patterns: (3) mural nodules with solid areas
of a cyst wall containing an anaplastic carcinoma or sarcoma
component; (4) background endometriosis; and (5) association
with primary ovarian sex -cord or germ cell tumor [8]. Even with
the assistance of pathologic evaluation, and especially during
frozen pathology, many cases are still considered to be primary
ovarian cancers.
Recent evidence supports the possible role of informative
immunohistochemistry in distinguishing primary from secondary
mucinous ovarian cancers [15e17]. McCluggage [17] extensively
reviewed the topic of the use of immunohistochemistry to distin-
guish between primary and metastatic ovarian mucinous neo-
plasms. Immunohistochemical analysis of primary ovarian
Table 1
Frequently used immunohistocytologic markers of primary and secondary ovarian mucinous carcinomas.
Tumors Primary Secondary
Markers Intestinal Mullerian Colorectal Pancreatic Biliary Gastric Cervical
CK7 þ/þþ þþ Neg þ/þþ þ/þþ þ/þþ þþ
CK20 þ/þþ Neg þþ Neg/þ Neg/þ Neg/þ Neg/þ
CDX2 þ Neg þþ þ þ þ Neg/þ
CA 125 Neg þþ Neg þ/þþ þ/þþ Neg þþ
CA 19-9 þþ Neg/þ þþ þþ þþ þþ Neg
CEA þ/þþ Neg þþ þ/þþ þ/þþ þ/þþ þ/þþ
p16 Neg Neg Neg/þ Neg Neg Neg þþ
ER Neg þþ Neg Neg Neg Neg Neg/þ
DPC4 þþ þþ þþ þ/þþ þ/þþ þþ þþ
PAX8 þþ þþ Neg Neg Neg Neg Neg/þ
þ ¼ focal positive; þþ ¼ diffuse positive; CK ¼ cytokeratin; CDX2 ¼ nuclear transcription factor CDX2; CA ¼ carbohydrate antigen; CEA ¼ carcinoembryonic antigen;
DPC4 ¼ nuclear transcription factor DPC4; Neg ¼ negative; PAX8 ¼ paired box transcription factor 8.
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ovarian tumor from the lower GI tract is often positive to CK20. In
addition, since human papilloma virus (HPV) is absent or only
rarely detected in primary ovarian neoplasia (more than 90% of
cervical adenocarcinomas of “usual” histological type are HPV
positive), if the diagnosis is challenged, a HPV test could be tried in
our current case. Finally, we list the frequently used markers in
Table 1, and these markers could provide additional information to
help diagnosis.
We may attempt to use tumor markers to distinguish primary
from secondary, but the value is limited, since CA 125, CA 19-9, and
CEA levels might be elevated in both conditions. A recent publica-
tion from Japan proposed new predictive algorithms for diagnosing
primary and metastatic mucinous carcinomas of the ovary,
including a combination of tumor size, patient age, serum CA19-9
and serum CA 125, which provided more accurate pre- and intra-
operative diagnoses [18]; however, this approach also failed to help
in our reported case. Radiological examinations, such as ultrasound
and computed tomography, added little information about this
patient, because she presented with an ovarian cystic mass lesion
accompanied with massive ascites.
Finally, our current patient could be considered as an accidental
diagnosis of far-advanced cervical cancer (FIGO Stage IV). Although
surgery might not be the treatment of choice, the patient was
treated with immediate postoperative adjuvant systemic chemo-
therapy of eight cycles of topotecan plus cisplatin with a 15-month
disease-free survival, suggesting that this strategy in the manage-
ment of patients in a similar situation could be considered. How-
ever, a recent report from the University of Texas Southwestern
Medical Center suggested that surgical evaluation of adnexal
masses in patients with cervical cancer can be considered to opti-
mize treatment outcomes, since the authors found that 23% of
surgically managed patients and 57% of conservatively managed
patients had disease recurrence (p ¼ 0.05), but the authors also
suggested that patients with cystic masses less than 8 cm and
complex masses less than 5 cm in size can be expectantly managed
[19]. Our patient had a 15 cm adnexa mass, suggesting that this
accidental removal of metastatic ovarian tumor secondary to
endocervical adenocarcinoma was an acceptable choice, according
to the above-mentioned report [19].
In conclusion, endocervical adenocarcinoma metastatic to the
ovary mimicking a primary ovarian tumor is still a challenge. Based
on this report, effort should be made to minimize the risk of a
delayed diagnosis of primary endocervical adenocarcinoma.
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